ARL8A

Across TCGA pan-cancer cohorts, ARL8A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARL8A data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARL8A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL8A expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

UCEC, LSCC, and GBM are the cancer types where ARL8A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.414	0.950	<.001	26	view →
LSCC	DFS	Tertile	All	0.570	0.801	.019	8	view →
GBM	OS	Tertile	All	0.515	0.275	.018	5	view →
CCRCC	OS	Median	All	1.000	0.914	.027	4	view →
LUAD	OS	Median	III,IV	0.283	0.735	.025	2	view →
HNSC	OS	Quartile	All	0.603	0.828	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARL8A–UCEC (DFS)

Open the UCEC breakdown →